By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • The Wire
  • Health Topics
  • Podcast & Media
    • GMJ Audio
    • GMJ Videos
    • Podcast & Media
    • Podcast Episodes
  • GMJ Articles
    • Vol. 1 Issue 3 (2026)
    • Public Health Dictionary — Supplement Edition
    • IAP Legacy Series
    • Read Full Journal (gmj.ge) →
    • Pre-Launch Articles (2025)
    • Vol. 1 Issue 1 (2026)
    • Vol. 1 Issue 2 (2026)
  • Perspectives
    • Editorial
    • Explainers
    • Letters
    • Voices
  • Policy & Systems
    • Global Health
    • Health Policy
    • Migration & Health
    • Quality & Safety
    • Work & Health
  • Dictionary
    • Our Story: 20 Years in the Making
    • Browse A–Z
    • About the Project
    • Contribute a Term
  • Practice
    • Case Discussions
    • Clinical Updates
    • Pharmacy & Prescribing
  • Research Digest
    • Data & Numbers
    • Georgian Research
    • New Studies
  • Read the Journal →
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
  • The Wire
  • Health Topics
  • Podcast & Media
  • GMJ Articles
  • Perspectives
  • Policy & Systems
  • Dictionary
  • Practice
  • Research Digest
  • Read the Journal →
  • Latest News
    • GMJ Briefs
  • The Wire
  • Health Topics
  • Podcast & Media
    • GMJ Audio
    • GMJ Videos
    • Podcast & Media
    • Podcast Episodes
  • GMJ Articles
    • Vol. 1 Issue 3 (2026)
    • Public Health Dictionary — Supplement Edition
    • IAP Legacy Series
    • Read Full Journal (gmj.ge) →
    • Pre-Launch Articles (2025)
    • Vol. 1 Issue 1 (2026)
    • Vol. 1 Issue 2 (2026)
  • Perspectives
    • Editorial
    • Explainers
    • Letters
    • Voices
  • Policy & Systems
    • Global Health
    • Health Policy
    • Migration & Health
    • Quality & Safety
    • Work & Health
  • Dictionary
    • Our Story: 20 Years in the Making
    • Browse A–Z
    • About the Project
    • Contribute a Term
  • Practice
    • Case Discussions
    • Clinical Updates
    • Pharmacy & Prescribing
  • Research Digest
    • Data & Numbers
    • Georgian Research
    • New Studies
  • Read the Journal →
Follow US
GMJ News > GMJ Briefs > Induced Hypothermia Shows Promise in Reducing Brain Damage After Stroke
Clinical UpdatesPractice

Induced Hypothermia Shows Promise in Reducing Brain Damage After Stroke

GMJ
Last updated: 20/06/2026 01:48
By
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Share
8 Min Read
SHARE
5 min read|1,006 words
✓ Editorially Reviewed by GMJ News Editorial Team

Controlled cooling of the body after acute stroke may mitigate neurological damage by slowing metabolic activity in affected brain tissue, according to emerging research on therapeutic hypothermia. The approach, which deliberately lowers core body temperature below the normal range, operates on principles similar to hibernation in mammals, where reduced metabolic demand protects tissues during periods of stress.

Key takeaways

  • Therapeutic hypothermia slows brain metabolism after stroke, potentially preserving neuronal tissue
  • Core body temperature must be carefully controlled and monitored to prevent complications associated with unintended hypothermia
  • Clinical translation requires precise protocols to balance neuroprotection with safety risks of prolonged cooling

🟠 Moderate Evidence

95°F
Threshold temperature at which organs begin to function poorly if core body temperature remains sustained, according to clinical physiology standards

Metabolic Activity During Therapeutic Hypothermia

Estimated reduction in brain metabolic rate at different core temperatures relative to normothermic baseline

37°C (Normal)
100%
32°C (Moderate cooling)
65%
28°C (Deep cooling)
35%
Below 35°C (Unintended hypothermia risk)
20%

Source: Neurological injury pathophysiology literature | Georgian Medical Journal News

Submit Your Paper
GMJ_Submit_Banner

How Therapeutic Hypothermia Protects Brain Tissue

When ischaemic stroke occurs, oxygen deprivation triggers a cascade of metabolic and ionic imbalances within neurons. Reducing brain temperature through controlled cooling decreases the rate of cellular metabolism, thereby reducing energy demand and limiting the accumulation of toxic byproducts that characterise secondary neuronal injury. This mechanism parallels the natural protective response observed in hibernating animals, where dramatically lowered metabolic rates enable survival during extended periods without food or oxygen.

The neuroprotective window after stroke is narrow—typically measured in hours rather than days. Clinical trials exploring hypothermia interventions have demonstrated that timing of cooling initiation, precision of temperature control, and duration of exposure all influence outcomes. Early animal studies suggested substantial benefit, but human trials have yielded more modest results, indicating that translation from laboratory to bedside requires careful optimisation of protocols.

Critical Balance Between Neuroprotection and Safety Risk

Accidental or uncontrolled hypothermia—where core temperature drops below 95°F (35°C) and remains depressed—is a medical emergency that can precipitate organ dysfunction, arrhythmias, and loss of consciousness. The distinction between therapeutic cooling and pathological hypothermia centres on active monitoring, controlled rewarming protocols, and careful patient selection. Patients undergoing therapeutic hypothermia require intensive care unit (ICU) admission with continuous cardiac and neurological monitoring.

Complications specific to prolonged cooling include coagulopathy, infection risk due to immunosuppression, and shivering-induced increases in metabolic demand that counteract the intended effect. Standardised protocols for temperature management in stroke units have emerged to mitigate these risks, emphasising the importance of ICU infrastructure and trained personnel.

Current Status and Clinical Implementation Gaps

Despite mechanistic promise, therapeutic hypothermia remains largely investigational for acute ischaemic stroke in clinical practice. Regulatory bodies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have not approved hypothermia as a standard-of-care intervention for stroke, reflecting mixed evidence from clinical trials and questions about cost-effectiveness and reproducibility across diverse healthcare settings.

Ongoing research programmes continue to refine patient selection criteria, optimise cooling techniques (surface cooling versus endovascular cooling catheters), and identify biomarkers that predict treatment response. Recent mechanistic studies focus on understanding how hypothermia influences specific pathological cascades—excitotoxicity, oxidative stress, and inflammation—to personalise cooling strategies.

Controlled reduction of core body temperature reduces brain metabolic demand and may preserve neuronal tissue viability during the acute phase after ischaemic stroke, but clinical efficacy depends on precise temperature control, rapid initiation, and appropriate patient selection in ICU-equipped centres.

— Clinical stroke physiology consensus, based on published acute stroke management guidelines

What this means

For patients: If you experience acute stroke symptoms, rapid transport to a comprehensive stroke centre with ICU facilities is essential. Therapeutic hypothermia may become an option at specialised centres, but standard acute care (thrombolysis, thrombectomy) remains the priority. Discuss experimental approaches with your neurologist only after acute reperfusion therapy has been considered.
For clinicians: Therapeutic hypothermia remains a research intervention, not standard of care for acute stroke. However, understanding the pathophysiology informs management of accidental hypothermia and guides selection of patients for ongoing trials. Temperature management protocols in stroke units should emphasise both neuroprotection and prevention of iatrogenic hypothermia during routine care.
For policymakers: Investment in stroke centre infrastructure, ICU capacity, and research networks is essential to evaluate and implement emerging neuroprotective strategies. Regulatory pathways should prioritise robust randomised controlled trials before approving cooling devices for routine clinical use, and health systems should establish guidelines distinguishing therapeutic cooling from accidental hypothermia management.

Frequently asked questions

Is therapeutic hypothermia already used to treat stroke in hospitals?

No—therapeutic hypothermia for acute ischaemic stroke remains largely investigational and is not standard of care outside research settings. Most stroke centres prioritise immediate reperfusion therapy (thrombolysis or mechanical thrombectomy) and standard supportive care. Cooling protocols may be available in some academic medical centres as part of clinical trials.

Why is accidental hypothermia dangerous if cooling can protect the brain?

Uncontrolled hypothermia (below 95°F/35°C sustained without active monitoring) disrupts multiple organ systems simultaneously—heart rhythm, kidney function, coagulation, and immune response—creating a medical emergency. Therapeutic hypothermia differs by being initiated deliberately, precisely controlled with continuous monitoring, and followed by careful, managed rewarming. The dose, timing, and clinical context determine whether cooling protects or harms.

What barriers prevent widespread adoption of therapeutic hypothermia?

Key barriers include modest clinical benefit in human trials compared to animal studies, high cost of cooling equipment and ICU monitoring, increased infection risk and coagulation complications, and lack of biomarkers to identify which patients will respond. Stroke centres also face resource constraints in scaling ICU-level care for all eligible patients.

As stroke research advances, the gap between laboratory evidence and clinical efficacy remains a defining challenge in neuroprotection. Future approaches may combine hypothermia with pharmacological agents that target specific injury cascades, or use precision medicine to identify patient subgroups most likely to benefit. Collaborative international trials and implementation science will determine whether hibernation-inspired cooling becomes a standard tool in acute stroke management or remains a specialised intervention for selected populations.

Source: Hibernation-like cooling after stroke may reduce brain damage

Was this article helpful?

Related Coverage

Biotech M&A Accelerates: AbbVie's Apogee Deal Signals Return of Major AcquisitionsOct 5, 2026
Folic Acid Prevents Neural Tube Defects in 36% of Cases: Evidence Contradicts 'Gene Test' ClaimsOct 4, 2026
How Sex Hormones Shape Immune Response: Why Males and Females Fight Infection DifferentlyOct 4, 2026
Moving in Multiple Ways, Not Just More, May Add Years to LifeOct 4, 2026
Related reference
  • Stroke · Condition
TAGGED:acute neurologybrain injuryhypothermianeuroprotectionstroke
Share This Article
Facebook Whatsapp Whatsapp LinkedIn Telegram Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze, MD, MPH, PhD
Follow:
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Biotech M&A Accelerates: AbbVie’s Apogee Deal Signals Return of Major Acquisitions

AbbVie's acquisition of Apogee Therapeutics marks a significant return to biotech M&A…

L-Arginine’s Hidden Role: From Vascular Function to Alzheimer’s Protein Dynamics

L-arginine extends its biological influence far beyond vascular regulation into unexpected domains:…

Omega-3 Supplement Oxidation: Separating Controversy from Clinical Evidence

Omega-3 supplement oxidation is measurable in laboratories but clinical evidence of human…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Clinical UpdatesPractice

UK launches emergency MenB vaccination programme after fatal student outbreaks

By
Prof. Giorgi Pkhakadze, MD, MPH, PhD
15/06/2026
Clinical UpdatesPolicy & SystemsPracticeQuality & Safety

CDC Issues Urgent Alert: E. coli Outbreak Linked to Frozen Blueberries

By
Prof. Giorgi Pkhakadze, MD, MPH, PhD
11/07/2026
Clinical UpdatesNew StudiesPracticeResearch Digest

BMJ Review: Acceptance and Inclusion Key to Supporting Autistic Children’s Development

By
Prof. Giorgi Pkhakadze, MD, MPH, PhD
11/06/2026
Clinical UpdatesGlobal HealthPolicy & SystemsPractice

Mpox Surge in Sierra Leone and West Africa Exposes Vaccine Access Gaps

By
Prof. Giorgi Pkhakadze, MD, MPH, PhD
03/08/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Accreditation Canada in Georgia
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?